Editorial: Key role of nuclear medicine in bringing imaging biomarkers into clinical practice

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 12, 2009, Pages 1937-1939

  Carrió, Ignasi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BIOLOGICAL MARKER;

CLINICAL PRACTICE; DIAGNOSTIC IMAGING; EDITORIAL; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE DIAGNOSIS; TECHNOLOGY; METABOLISM; METHODOLOGY; NUCLEAR MEDICINE; PUBLICATION;

BIOLOGICAL MARKERS; HUMANS; MOLECULAR IMAGING; NUCLEAR MEDICINE; PERIODICALS AS TOPIC;

EID: 71849106318     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1318-3     Document Type: Editorial

References (10)

1. SM Larson 2008 Practice-based evidence of the beneficial impact of positron emission tomography in clinical oncology J Clin Oncol. 26 13 2083 4 10.1200/JCO.2007.15.6935 18362363
2. R Hachamovitch 2009 Assessing the prognostic value of cardiovascular imaging: a statistical exercise or a guide to clinical value and application Circulation 120 14 1342 4 10.1161/CIRCULATIONAHA.109.893388 19770390
3. PJ Visser DS Knopman 2009 Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnesic MCI Neurology 73 10 744 5 10.1212/WNL.0b013e3181b61b5d 19641169
4. Hosking CR, Schwartz JL. The future's bright: Imaging cell biology in the 21st century. Trends Cell Biol 2009; ahead of print.
5. T Beyer B Pichler 2009 Eur J Nucl Med Mol Imaging. 36 S1 144 10.1007/s00259-008-1041-5 19104807
6. F Lordick K Ott B Krause 2007 PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet 8 9 797 805 10.1016/S1470-2045(07)70244-9 (Pubitemid 47308659)
7. I Carrió 2008 Of Impact, metrics and ethics Eur J Nucl Med Mol Imaging. 35 1049 50 10.1007/s00259-008-0790-5 18414852
8. Y Li JO Rinne L Mosconi, et al. 2008 Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease Eur J Nucl Med Mol Imaging. 35 2169 81 10.1007/s00259-008-0833-y 18566819
9. G Kramer-Marek DO Kiessewetter L Martinova, et al. 2008 (18F)FBEM-ZHER2:342-Affibody Molecule- a new molecular tracer for in-vivo monitoring of HER2 expression by positron emission tomography Eur J Nucl Med Mol Imaging. 35 1008 18 10.1007/s00259-007-0658-0 1:CAS:528:DC%2BD1cXkvVyjuro%3D 18157531
10. GW Goerres R Stupp G Barghouth, et al. 2005 The value of PET, CT, and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging. 32 153 62 10.1007/s00259-004-1633-7 1:CAS:528:DC%2BD2MXpsFyktQ%3D%3D 15690223 (Pubitemid 40248485)